iBio, Inc.
IBIOHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, iBio, Inc. (IBIO) is listed under Biotechnology. The company carries a $35.7M market cap, placing it firmly in the micro-cap category. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Market Cap
$35.7M
Beta
1.26
P/E (TTM)
—
P/E (Fwd)
-1.17
EPS (TTM)
$-0.29
EPS (Fwd)
$-0.61
ROE
-65.7%
ROA
-30.8%
Cash
$88.0M
Total Debt
$2.2M
Free CF
-$13.6M
52W Change
-40.5%
Annual Financials
Cash vs Debt
Where IBIO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IBIO finished 51.28% below its 150-day moving average ($1.56) and 56.82% below its 200-day moving average ($1.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IBIO overbought or oversold?
At the October 20, 2026 close, IBIO's RSI(14) was 11.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
iBio, Inc. holds $88.0M in cash against $2.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$13.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -65.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IBIO.